Almirall looks for new M&A to continue expanding in the dermatology market

23 February 2016

Spain’s leading drugmaker Almirall (ALM: MC) discussed its strategy with The Pharma Letter’s local correspondent, explaining why it has moved out of the respiratory sector to focus on dermatology.

“When we hit the market with Eklira (aclidinium), competition in the respiratory sector was stiff from big pharmaceutical companies. Along with this was the austerity in the pharmaceutical sector in Spain. Despite the difficulties, we were doing well but at a very high cost. That was when we took the decision to transfer the rights of our respiratory franchise to AstraZeneca [LSE: AZN]."

Almirall sold the franchise to the Anglo-Swedish pharma major for an initial $875 million and up to $1.22 billion in development and other sales-related milestones (The Pharma Letter November 3, 2014). The Spanish firm says it is now looking for new acquisitions to grow its dermatology business that provided 43.1% of total sales according to the last full year 2015 results, from 37% in 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK